At week 36, patients taking the highest dose of Elecoglipron had shed nearly 12% of their body weight—a threshold that medical guidelines often recommend for reducing obesity-related disease risk. The finding marks a turning point in how doctors might treat obesity without needles, offering hope to millions who fear injections.
Elecoglipron is a once-daily oral GLP-1 receptor agonist, a class of drugs that has transformed obesity treatment over the past few years. Injectable versions have proven remarkably effective, but many patients avoid them. Beyond needle anxiety, injectables require refrigerated transport and storage, adding cost and logistical complexity. Elecoglipron sidesteps these barriers. It's a small-molecule pill that can be taken at any time of day, with no restrictions on food or drink—a meaningful advantage over existing oral alternatives like semaglutide, which demands strict fasting conditions.
The Phase II trial, called VISTA, tested the drug across seven countries with 310 adults living with obesity or overweight who did not have diabetes. Over 36 weeks, researchers gave participants varying doses of Elecoglipron—ranging from 5 mg to 75 mg—or a placebo, tracking how their bodies responded. The results, published in The Lancet, show clear dose-dependent effects. Those taking 5 mg lost an average of 2.6% of baseline body weight by week 26. The 75 mg group lost 10.5% at the same checkpoint, then continued shedding weight to reach 11.8% by week 36. Even more striking: 89% of participants on the highest dose lost at least 5% of their body weight at 26 weeks, compared with just 16% in the placebo group.
The weight-loss momentum had not yet plateaued by study's end, suggesting patients might have lost even more had treatment continued. The drug also improved blood pressure and markers of inflammation like C-reactive protein, addressing multiple health concerns tied to obesity. These improvements matter because obesity is far more than a matter of willpower. It stems from a complex interplay of genetic, social, environmental, and economic factors, and it significantly raises the risk of type 2 diabetes, cardiovascular disease, and in young people, mental health struggles from bullying and lower quality of life.
The most common side effects were gastrointestinal: nausea, constipation, diarrhea, and vomiting. For most participants, these were mild to moderate and most noticeable in early treatment as bodies adjusted to the medication. This safety profile is broadly consistent with other GLP-1 drugs, suggesting Elecoglipron follows a familiar playbook.
The breakthrough carries real-world significance. Since injectable GLP-1 agonists gained prominence, many patients have struggled to maintain treatment due to injection anxiety—a barrier that affects adherence and outcomes. An effective pill without food restrictions could transform access and compliance. The next phase will test whether these Phase II results hold up in larger, longer studies. If they do, Elecoglipron could offer patients a genuinely convenient alternative that doesn't require a cold chain or a needle, expanding options for a condition that affects hundreds of millions worldwide.